CLAIMS:

1. A method of treating schizophrenia or bipolar disorder in a patient comprising:

   subcutaneously administering to the patient, with a frequency of no more than once per 21 days, a sustained-release pharmaceutical dosage form comprising olanzapine, or a pharmaceutically acceptable salt thereof;

   wherein the dosage form provides a therapeutically effective dose of olanzapine for a period of at least 21 days; and

   wherein said method is performed without monitoring for post-injection delirium/sedation syndrome (PDSS).

2. The method of claim 1, wherein the pharmaceutical dosage form comprises olanzapine.

3. The method of claim 1, wherein the pharmaceutical dosage form comprises a pharmaceutically acceptable olanzapine salt.

4. The method of any one of the preceding claims, wherein the pharmaceutical dosage form comprises between about 150 mg and about 900 mg of olanzapine or a pharmaceutically acceptable salt thereof.

5. The method of claim 4, wherein the pharmaceutical dosage form comprises between about 300 mg and about 600 mg of olanzapine or a pharmaceutically acceptable salt thereof.

6. The method of claim 4, wherein the pharmaceutical dosage form comprises about 300 mg of olanzapine or a pharmaceutically acceptable salt thereof.

7. The method of claim 4, wherein the pharmaceutical dosage form comprises about 405 mg olanzapine or a pharmaceutically acceptable salt thereof.

8. The method of claim 4, wherein the pharmaceutical dosage form comprises about 600 mg olanzapine or a pharmaceutically acceptable salt thereof.

9. The method of claim 1, wherein the pharmaceutical dosage form further comprises at least one biodegradable polymer.

10. The method of claim 9, wherein the at least one biodegradable polymer is a poly(lactide), poly(glycolide), poly(lactide-co-glycolide), poly-1-lactic acid, poly-d-lactic acid, poly(glycolic acid), copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-captolactone), poly(amino acid), polyesteramide, polyanhydrides, polyphosphazines, poly(alkylene alkylate), biodegradable polyurethane, polyvinylpyrrolidone, polyalkanoic acid, polyethylene glycol, copolymer of polyethylene glycol and polyorthoester, albumin, chitosan, casein, waxes or blends or copolymers thereof.

11. The method of any one of the preceding claims, wherein the pharmaceutical dosage form provides a therapeutically effective dose of olanzapine for at least about 30 days.

12. The method of claim 11, wherein the pharmaceutical dosage form provides a therapeutically effective dose of olanzapine for at least about 60 days.

13. The method of claim 11, wherein the pharmaceutical dosage form provides a therapeutically effective dose of olanzapine for about 90 days.

14. A method of administering between about 150 mg and about 900 mg of olanzapine, or a pharmaceutically acceptable salt thereof, to a patient comprising: subcutaneously administering

to the patient a sustained-release olanzapine pharmaceutical dosage form at a frequency of no more than once per 21 days;

wherein the per-injection risk of PDSS being observed in the patient following the administration is less than 0.07% and/or the per-patient risk of PDSS being observed in the patient following the administration is less than 1.4%.

15. The method of claim 14, wherein the frequency of administration is no more than once per month.

16. The method of claim 15, wherein the frequency of administration is no more than once every two months.

17. The method of any one of claims 14 to 16, wherein the pharmaceutical dosage form comprises between about 300 mg and about 600 mg of olanzapine or a pharmaceutically acceptable salt thereof.

18. The method of claim 17, wherein the pharmaceutical dosage form comprises about 300 mg of olanzapine or a pharmaceutically acceptable salt thereof that is equivalent to about 300 mg of olanzapine.

19. The method of claim 17, wherein the pharmaceutical dosage form comprises about 405 mg olanzapine or a pharmaceutically acceptable salt thereof that is equivalent to about 405 mg of olanzapine.

20. The method of claim 17, wherein the pharmaceutical dosage form comprises about 600 mg olanzapine or a pharmaceutically acceptable salt thereof that is equivalent to about 600 mg of olanzapine.

21. The method of any one of claims 14 to 20, wherein the pharmaceutical dosage form further comprises at least one biodegradable polymer.

22. The method of claim 21, wherein the at least one biodegradable polymer is a poly(lactide), poly(glycolide), poly(lactide-co-glycolide), poly-1-lactic acid, poly-d-lactic acid, poly(glycolic acid), copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-captolactone), poly(amino acid), polyesteramide, polyanhydrides, polyphosphazines, poly(alkylene alkylate), biodegradable polyurethane, polyvinylpyrrolidone, polyalkanoic acid, polyethylene glycol, copolymer of polyethylene glycol and polyorthoester, albumin, chitosan, casein, waxes or blends or copolymers thereof.

23. The method of any one of claims 14 to 22, wherein the pharmaceutical dosage form provides a therapeutically effective dose of olanzapine for at least about 30 days.

24. The method of claim 23, wherein the pharmaceutical dosage form provides a therapeutically effective dose of olanzapine for at least about 60 days.

25. The method of claim 24, wherein the pharmaceutical dosage form provides a therapeutically effective dose of olanzapine for about 90 days.

26. The method of any one of claims 14 to 22, wherein the per-injection risk of PDSS being observed in the patient following the administration is less than 0.01%.

27. The method of claim 26, wherein the per-injection risk of PDSS being observed in the patient following the administration is less than 0.005%.

28. The method of claim 26, wherein the per-injection risk of PDSS being observed in the patient following the administration is less than 0.001%.

29. The method of claim 26, wherein the per-injection risk of PDSS being observed in the patient following the administration is less than 0.0005%.

30. The method of claim 26, wherein the per-injection risk of PDSS being observed in the patient following the administration is 0%.

31. The method of any one of claims 14 to 22, wherein the per-patient risk of PDSS being observed in the patient is less than 1.4%.

32. The method of claim 31, wherein the per-patient risk of PDSS being observed in the patient is less than 1%.

33. The method of claim 31, wherein the per-patient risk of PDSS being observed in the patient is less than 0.75%.

34. The method of claim 31, wherein the per-patient risk of PDSS being observed in the patient is less than 0.5%.

35. The method of claim 31, wherein the per-patient risk of PDSS being observed in the patient is less than 0.25%.

36. The method of claim 31, wherein the per-patient risk of PDSS being observed in the patient is less than 0.1%.

37. The method of claim 31, wherein the per-patient risk of PDSS being observed in the patient is less than 0.05%.

38. The method of claim 31, wherein the per-patient risk of PDSS being observed in the patient is 0%.

39. The method of any one of claims 1 to 38, wherein the sustained-release olanzapine pharmaceutical dosage form releases less than 40 wt% of the olanzapine, based on the weight of the administered olanzapine, into human plasma at 1 hour.

40. The method of claim 39, wherein the pharmaceutical dosage form releases less than 30 wt% of the olanzapine, based on the weight of the administered olanzapine, into human plasma at 1 hour

41. The method of claim 39, wherein the pharmaceutical dosage form releases less than 20 wt% of the olanzapine, based on the weight of the administered olanzapine, into human plasma at 1 hour.

42. The method of claim 39, wherein the pharmaceutical dosage form releases less than 10 wt% of the olanzapine, based on the weight of the administered olanzapine, into human plasma at 1 hour.

43. The method of claim 39, wherein the pharmaceutical dosage form releases less than 5 wt% of

the olanzapine, based on the weight of the administered olanzapine, into human plasma at 1 hour.

44. The method of claim 39, wherein the pharmaceutical dosage form releases less than 3 wt% of the olanzapine, based on the weight of the administered olanzapine, into human plasma at 1 hour.

45. The method of claim 39, wherein the pharmaceutical dosage form releases less than 1 wt% of the olanzapine, based on the weight of the administered olanzapine, into human plasma at 1 hour.

46. The method of any one of claims 14 to 45, wherein the patient has been diagnosed with schizophrenia.

47. The method of any one of claims 14 to 45, wherein the patient has been diagnosed with bipolar disorder.